Mixed data on bepranemab in early Alzheimer’s

Belgium’s largest drugmaker UCB (Euronext: UCB) has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease.

The results were presented during a late-breaking symposium at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) meeting (Madrid, Spain, October 29 – November 1, 2024), and come just days after UCB revealed that Swiss pharma giant Roche (ROG: SIX) had decided to return all global rights to Alzheimer’s candidate bepranemab following termination of their collaboration agreement.

“We are deeply encouraged by the proof-of-concept data for bepranemab, which highlight its potential to impact early Alzheimer’s disease progression. This strengthens our belief in the value of targeting the mid-region of tau as an important strategy in altering the trajectory of the disease," said Alistair Henry, chief scientific officer at UCB. "